Vaccitech plc (VACC)

NASDAQ: VACC · IEX Real-Time Price · USD
4.98
+0.47 (10.42%)
Aug 16, 2022 11:04 AM EDT - Market open
10.42%
Market Cap 185.34M
Revenue (ttm) 32.10M
Net Income (ttm) -1.38M
Shares Out 37.22M
EPS (ttm) 0.41
PE Ratio 12.15
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,158
Open 4.68
Previous Close 4.51
Day's Range 4.64 - 4.98
52-Week Range 2.97 - 16.50
Beta n/a
Analysts Buy
Price Target 20.40 (+309.6%)
Earnings Date Aug 11, 2022

About VACC

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-... [Read more...]

Industry Biotechnology
IPO Date Apr 30, 2021
Employees 72
Stock Exchange NASDAQ
Ticker Symbol VACC
Full Company Profile

Financial Performance

In 2021, Vaccitech's revenue was $268,000, a decrease of -94.44% compared to the previous year's $4.82 million. Losses were -$50.87 million, 187.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for VACC stock is "Buy." The 12-month stock price forecast is 20.4, which is an increase of 309.64% from the latest price.

Price Target
$20.4
(309.64% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

OXFORD, United Kingdom, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Co...

Vaccitech to Present at the William Blair Biotech Focus Conference 2022

OXFORD, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics an...

Vaccitech's Vaccine Induced Sustained Reductions In Hepatitis B Associated Antigens

Vaccitech plc (NASDAQ: VACC) announced an update to the interim analysis of safety and efficacy data from the HBV002 study evaluating ChAdOx1-HBV and MVA-HBV vaccines (VTP-300) in chronic HBV patients w...

Vaccitech's VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a mo...

VTP-300 as a monotherapy and in combination with a single administration of low-dose nivolumab was administered, with no treatment-related serious adverse events and infrequent transient transaminitis.

Vaccitech to Present at the Jefferies Healthcare Conference

OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics an...

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic ...

Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA therapy Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeuti...

Vaccitech to Present at the H.C. Wainwright Global Investment Conference

OXFORD, United Kingdom, May 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and...

Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments

OXFORD, United Kingdom, May 11, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the first quarter ended March 31, 2022, and provided an overview of the Co...

Vaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria®

Revenue Sharing Arrangement with University of Oxford Could Deliver Further Payments to Vaccitech Arising from Milestones and Royalties Revenue Sharing Arrangement with University of Oxford Could Delive...

Vaccitech Reports Full-Year 2021 Financial Results and Recent Corporate Developments

OXFORD, United Kingdom, March 25, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the full year ended December 31, 2021 and provided an overview of the Co...

Vaccitech to Present at the Barclays Global Healthcare Conference 2022

OXFORD, United Kingdom, March 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics a...

Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

OXFORD, United Kingdom, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Cancer Research UK, Vaccitech plc (Nasdaq: VACC) and the Ludwig Institute for Cancer Research (Ludwig), today announce the first patient dosed i...

Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, ...

Live webcast will be at 8:30 a.m. EST on January 25 Live webcast will be at 8:30 a.m. EST on January 25

Wall Street Analysts Believe Vaccitech PLC Sponsored ADR (VACC) Could Rally 113%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 112.8% in Vaccitech PLC Sponsored ADR (VACC). While the effectiveness of this highly sought-after metric is quest...

Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunothera...

A conference call and webcast will be held on December 14, 2021, at 8:30 a.m. EST (1:30 p.m. GMT). The webcast link and presentation can be found on the Events section of the Vaccitech website here .

Vaccitech Posts Interim Efficacy Data From Early-Stage Hepatitis B Trial

Vaccitech plc (NASDAQ: VACC) has announced an interim analysis of safety and efficacy data of VTP-300 from the HBV002 study, including a review of surface antigen (HBsAg) levels in chronic Hepatitis B p...

Vaccitech to Participate at The 33rd Annual Virtual Piper Sandler Healthcare Conference

OXFORD, United Kingdom, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics an...

Vaccitech Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

OXFORD, United Kingdom, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter, ended September 30, 2021, and provided an overview of ...

Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the ME...

The Phase 1 clinical trial was conducted by The King Abdullah International Medical Research Centre (KAIMRC), in the Kingdom of Saudi Arabia (KSA), in partnership with the University of Oxford. Vaccitec...

Vaccitech Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

OXFORD, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter, ended June 30, 2021, and provided an overview of the ...

Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B

Arbutus Biopharma Corporation (NASDAQ: ABUS) and Vaccitech plc (NASDAQ: VACC) have collaborated to evaluate combination treatment for chronic hepatitis B virus who are already receiving standard-of-care...

Other symbols: ABUS

Vaccitech Reports First Quarter 2021 Financial Results and Recent Corporate Developments

OXFORD, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics an...

Vaccitech Announces Closing of $110.5 Million Initial Public Offering

OXFORD, United Kingdom, May 04, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and...

VACC Stock IPO: 7 Things to Know as Vaccitech Starts Trading Today

Here's how VACC stock has performed thus far following the company's highly anticipated IPO in the market today. The post VACC Stock IPO: 7 Things to Know as Vaccitech Starts Trading Today appeared firs...